Docetaxel or Cisplatin radiosensitizer in Head and Neck cancer patients for curative or adjuvant chemoradiation

Tata Memorial Centre0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Participants must have a histologically confirmed stage III-IV squamous cell cancers of the head and neck region ( AJCC-UICC staging ,8th edition).
•2.Participants must warrant CTRT must warrant at least one of the following
•a.Radical setting : Stage III-IV head and neck cancer
•b.Adjuvant setting : Stage III-IV head and neck cancer postoperative with one of the below mentioned feature on pathology specimen
•i.Extracapsular extension
•ii.Margin positive
•iii.Close margin ( cut margin 0.5 mm or below)
•3.Participants must have malignancy arising from one of the following sites oral cavity, pharynx ( inclusive of oropharynx, hypopharynx) or larynx ( inclusive of supraglottis, glottis and subglottis) or CUP ( carcinoma unknown primary) with neck nodes
•4.ECOG performance status <=2
•5.Participants must have normal organ and marrow function as defined below:
•a.Leukocytes>=3,000/mcL
•b.Platelets>=100,000/mcL
•c.Total bilirubin < 1.5 Ã? institutional upper limit of normal
•d.AST(SGOT)/ALT(SGPT) <=1.5 Ã? institutional upper limit of normal
•e.Calculated Creatinine clearance > 50 ml/min

•1.Participants who are receiving any other investigational agents.
•2.Primary sites of malignancy major salivary gland or nasopharynx or skin
•3.Patients with QTc prolongation defined as QTc interval greater than 480 ms in view of risk of sudden cardiac death associated with use of antiemetics.
•4.History of allergic reactions attributed to compounds of similar chemical or biologic composition to any agents used in study.
•5.Uncontrolled intercurrent illness including, but not limited to tuberculosis, diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, renal failure (on dialysis), active gastrointestinal bleeding, cerebrovascular accidents, inflammatory bowel disease, known hyperkalemia ( CTCAE version 4.02 grade 3 or above which is persistent over 1 week) or psychiatric illness/social situations that would limit compliance with study requirements.
•6.Presence of grade 3 or above sensory hearing loss
•7.Pregnant women and breastfeeding women are excluded from this study because docetaxel has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants. These potential risks may also apply to other agents used in this study.
•8.HIV-positive, Active Hepatitis B and Active Hepatitis C seropositive patients are excluded from this study.

发起方